Advanced Research of Oncogene and Therapy Targets in Human Cancers
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 838
Special Issue Editor
Special Issue Information
Dear Colleagues,
The past three decades have witnessed tremendous advances in cancer research. Cancer arises through a multistep, mutagenic process whereby cancer cells acquire a common set of properties, including unlimited proliferation potential, self-sufficiency in growth signals, and resistance to antiproliferative and apoptotic cues. Cancer cells are often physiologically dependent on the continued activity of specific oncogenes, where inactivation of a single critical oncogenic gene may induce apoptosis. Cancer cell dependency on single oncogenes has been explored for drug discovery, leading to the development of targeted therapies. Oncogene addiction strongly impacts the therapeutic response of tumors to acute oncoprotein inhibition. An important implication of oncogene addiction is that inhibiting this critical pathway on which cancer cells become dependent can cause selective and specific cell death in cancer cells while sparing normal surrounding cells that are not oncogene-addicted. However, the mechanism by which cancer cells become dependent on a single pathway or activated oncoprotein is not precisely understood in most cases. Thus, a better understanding of oncogene may provide a rationale for improving current cancer therapies and aid in the development of novel therapeutic strategies for the management of cancer. This Special Issue of Biomedicines focuses on recent advances in this area, with a goal to stimulate advanced research and clinical interest in the exciting field of oncogene and therapy targets in human cancers.
Dr. Zhongqiu Xie
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer research
- therapy target
- oncogene
- human cancers
- translational medicine
